Zhong Guo Jing Ji Wang·2025-09-22 06:57Core Viewpoint - Junshi Biosciences (688180.SH) reported a significant increase in revenue for the first half of 2025, achieving 1.168 billion yuan, a year-on-year growth of 48.64%, while still facing net losses [1][3]. Financial Performance - The company's operating revenue for H1 2025 was 1.168 billion yuan, up from 0.785 billion yuan in the same period last year, reflecting a growth of 48.64% [1][3]. - The net profit attributable to shareholders was -413 million yuan, an improvement from -645 million yuan in the previous year [1][3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -478 million yuan, compared to -627 million yuan in the same period last year [1][3]. - The net cash flow from operating activities was -329 million yuan, an improvement from -865 million yuan year-on-year [1][3]. Historical Financial Data - From 2016 to 2024, the net profit attributable to shareholders showed a consistent trend of losses, with figures ranging from -135 million yuan to -2.388 billion yuan [3]. - The net profit after deducting non-recurring gains and losses also reflected similar losses, ranging from -160 million yuan to -2.490 billion yuan during the same period [3]. Capital Raising Activities - Junshi Biosciences was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 15, 2020, raising a total of 4.836 billion yuan, with a net amount of 4.497 billion yuan after expenses [4]. - The company planned to use the raised funds for innovative drug research and development, industrialization projects, repaying bank loans, and supplementing working capital [4]. - In 2022, the company raised an additional 3.776 billion yuan through a private placement of shares, with a net amount of approximately 3.745 billion yuan after expenses [5].